BiotechTube

GZ402666

Phase 1Completed
0 watching 0 views this week💤 Quiet
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pompe Disease

Conditions

Pompe Disease, Glycogen Storage Disease Type II (GSD II), Acid Maltase Deficiency

Trial Timeline

Aug 19, 2013 → Feb 25, 2015

NCT ID
NCT01898364

About GZ402666

GZ402666 is a phase 1 stage product being developed by Sanofi for Pompe Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01898364. Target conditions include Pompe Disease, Glycogen Storage Disease Type II (GSD II), Acid Maltase Deficiency.

Hype Score Breakdown

Clinical
10
Activity
5
Company
9
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01898364Phase 1Completed

Competing Products

20 competing products in Pompe Disease

See all competitors
ProductCompanyStageHype Score
S-606001 + PlaceboShionogiPhase 2
52
alglucosidase alfaSanofiApproved
84
alglucosidase alfa + PlaceboSanofiPhase 3
76
alglucosidase alfaSanofiApproved
84
glucosidase alfaSanofiPre-clinical
22
Alglucosidase alfaSanofiApproved
84
Avalglucosidase AlfaSanofiPhase 2
51
alglucosidase alfaSanofiApproved
84
MyozymeSanofiPhase 3
76
alglucosidase alfaSanofiApproved
84
alglucosidase alfaSanofiPre-clinical
22
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 3
76
Myozyme® (alglucosidase alfa) + Myozyme® (alglucosidase alfa)SanofiApproved
84
ALGLUCOSIDASE ALFASanofiApproved
84
alglucosidase alfa + alglucosidase alfaSanofiApproved
84
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 2
51
MyozymeSanofiPhase 2
51
MyozymeSanofiPhase 2
51
recombinant human acid alpha-glucosidase (rhGAA)SanofiPhase 2
51
Alglucosidase Alfa + Methotrexate + RituximabSanofiApproved
84

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84